How fast will I lose weight on Mounjaro?

What the trial data shows in the first weeks versus the full course

SURMOUNT-1 followed 2,539 adults with obesity over 72 weeks. Weight loss was not front-loaded: the largest drops accumulated as participants moved up through the dosing schedule, which typically takes several months to complete. At 2.5mg (the starting point) appetite suppression is present but modest; the body is adjusting rather than responding at full therapeutic intensity. By the time participants reached and sustained 10mg or 15mg, the cumulative losses were substantial.

Published weight curves from the trial show that most participants had lost around 5–8% of body weight by week 16. By week 36, the trajectory was steeper. The average 20–21% reduction at 15mg by week 72 represents a long, consistent downward trend rather than a dramatic early drop followed by a plateau. This matters because people sometimes expect fast, visible results in the first fortnight and feel discouraged when they don't appear. A gentler early phase is not a sign that treatment isn't working.

If you want a closer look at how fast you lose weight on Mounjaro, including what to expect in those early stages, our page covers that period in detail. The broader Mounjaro overview sets out how the medicine works mechanically.

Why the speed of loss differs from person to person

A question our prescribers hear most weeks is some version of: "My friend lost a stone in a month, why haven't I?" The answer usually comes down to four things working together: starting weight, dose reached, diet and activity changes made alongside treatment, and individual metabolic response.

Tirzepatide acts on two gut-hormone receptors, GIP and GLP-1, slowing gastric emptying and reducing appetite. But those signals land differently depending on a person's baseline hormone levels, gut motility, and how their body regulates hunger. Someone who tolerates dose increases quickly and reaches 15mg within a few months will, on average, lose weight faster than someone who stabilises at 7.5mg because higher doses cause side effects. Neither outcome is wrong, the prescriber's job is to find the highest dose that works without making the treatment unbearable.

Side effects, particularly nausea in the early weeks, also affect food intake in ways that aren't purely pharmacological. Early weight loss can sometimes be partly fluid-related. These early signals are real but not fully representative of how the body resets over months. If you're wondering how fast tirzepatide helps you lose weight at each stage of treatment, that page breaks down the timeline across the full course. For a broader look at how quickly you will lose weight on Mounjaro across the full treatment course, that page goes into timelines in more depth.

The NICE threshold and what it means in practice

NICE's guidance for tirzepatide (TA1026) includes a review point: if someone has lost less than 5% of their starting weight after six months at the highest dose they can tolerate, continuing treatment should be reconsidered. This isn't a failure marker, it's a built-in clinical checkpoint designed to make sure treatment is genuinely helping rather than running indefinitely without benefit.

Five percent of body weight over six months works out, for many people, to roughly half a kilogram per week on average, though the actual trajectory is rarely that steady. Some weeks nothing moves; others the change is sharper. The NICE appraisal of tirzepatide is publicly available and sets out the full eligibility and review criteria if you want to read the original wording.

Private treatment through a regulated service like ours follows the same clinical principles. Every repeat order goes through clinical review, which means our prescribers are checking progress, not just processing a renewal. Cost context for private treatment is worth understanding before you start, the Mounjaro price comparison page sets out what private Mounjaro typically costs in the UK and what the differences between providers usually reflect.

Setting realistic expectations without undermining motivation

The 20–21% average from SURMOUNT-1 is a striking number, but averages contain a wide spread. Some participants lost considerably more; others less. Weight loss is not a linear process on any treatment, and Mounjaro is no exception. Weight-loss stalls of a few weeks are common and do not indicate the medicine has stopped working.

What the evidence does support clearly is that tirzepatide, in the trial population, produced greater average weight loss than any previously licensed weight-management medicine in the UK, including semaglutide 2.4mg, as the SURMOUNT-5 head-to-head trial, published in the New England Journal of Medicine in 2025, confirmed. That comparison matters for people deciding between options, and our weight-loss treatment overview covers both Mounjaro and Wegovy to help with exactly that decision.

The right starting point is a conversation with a prescriber who can look at your medical history and starting weight and give you a realistic, personalised picture, not a forum post or an average from a press release. If you'd like a clearer sense of how fast Mounjaro will work for your situation before that conversation, our dedicated page walks through what shapes the timeline. When you're ready for that conversation, starting a free consultation is where it begins.